Gallium-68 DOTATOC for Management of Neuroendocrine Tumors

• Status: No longer available
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Gallium-68 DOTATOC is a material used to find neuroendocrine tumors (NETs) using positron emission tomography (PET scan). The material has already been shown to be better than the currently available imaging agents. This study is designed to evaluate the clinical impact of PET CT scanning using this agent in the evaluation and management of patients with NETs.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwell Health
• Treatments: Edotreotide; Octreotide

Criteria

Inclusion Criteria:

• Proven or suspected neuroendocrine tumor Physician referral for imaging

Exclusion Criteria:

• Pregnancy